CoChat

Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms

Open access
Riley, Brigit E., Gardai, Shyra J., Emig-Agius, Dorothea, Bessarabova, Marina, Ivliev, Alexander E., Schüle, Birgit, Alexander, Jeff, Wallace, William, Halliday, Glenda M., Langston, J. William, Braxton, Scott, Yednock, Ted, Shaler, Thomas, Johnston, Jennifer A. · 2014 · PLoS ONE
Cited by 86

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Detailed analysis of disease-affected tissue provides insight into molecular mechanisms contributing to pathogenesis. Substantia nigra, striatum, and cortex are functionally connected with increasing degrees of alpha-synuclein pathology in Parkinson's disease. We undertook functional and causal pathway analysis of gene expression and proteomic alterations in these three regions, and the data revealed pathways that correlated with disease progression. In addition, microarray and RNAseq experiments revealed previously unidentified causal changes related to oligodendrocyte function and synaptic vesicle release, and these and other changes were reflected across all brain regions. Importantly, subsets of these changes were replicated in Parkinson's disease blood; suggesting peripheral tissue may provide important avenues for understanding and measuring disease status and progression. Proteomic assessment revealed alterations in mitochondria and vesicular transport proteins that preceded gene expression changes indicating defects in translation and/or protein turnover. Our combined approach of proteomics, RNAseq and microarray analyses provides a comprehensive view of the molecular changes that accompany functional loss and alpha-synuclein pathology in Parkinson's disease, and may be instrumental to understand, diagnose and follow Parkinson's disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0102909

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 65

  1. JC Rochet, 2012, Molecular insights into Parkinson's disease, Prog Mol Biol Transl Sci, 107, 125, 10.1016/B978-0-12-385883-2.00011-4 · DOI
  2. MI Shadrina, 2010, Molecular mechanisms of pathogenesis of Parkinson's disease, Int Rev Cell Mol Biol, 281, 229, 10.1016/S1937-6448(10)81006-8 · DOI
  3. S Lesage, 2009, Parkinson's disease: from monogenic forms to genetic susceptibility factors, Hum Mol Genet, 18, R48, 10.1093/hmg/ddp012 · DOI · Paper page
  4. AH Schapira, 2011, Etiology and pathogenesis of Parkinson's disease, Mov Disord, 26, 1049, 10.1002/mds.23732 · DOI · Paper page
  5. H Braak, 2003, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 24, 197, 10.1016/S0197-4580(02)00065-9 · DOI · Paper page
  6. MG Cersosimo, 2011, Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients, Mov Disord, 26, 188, 10.1002/mds.23344 · DOI
  7. K Del Tredici, 2010, Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease, Acta Neuropathol, 119, 703, 10.1007/s00401-010-0665-2 · DOI · Paper page
  8. I Devic, 2011, Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease, Brain, 134, e178, 10.1093/brain/awr015 · DOI · Paper page
  9. KT Olde Dubbelink, 2014, Disrupted brain network topology in Parkinson's disease: a longitudinal magnetoencephalography study, Brain, 137, 197, 10.1093/brain/awt316 · DOI · Paper page
  10. MM Ponsen, 2012, A three dimensional anatomical view of oscillatory resting-state activity and functional connectivity in Parkinson's disease related dementia: An MEG study using atlas-based beamforming, Neuroimage Clin, 2, 95, 10.1016/j.nicl.2012.11.007 · DOI
  11. P Hickey, 2011, Available and emerging treatments for Parkinson's disease: a review, Drug Des Devel Ther, 5, 241
  12. WM Caudle, 2010, Using ‘omics’ to define pathogenesis and biomarkers of Parkinson's disease, Expert Rev Neurother, 10, 925, 10.1586/ern.10.54 · DOI
  13. PA Lewis, 2012, Gene expression in the Parkinson's disease brain, Brain Res Bull, 88, 302, 10.1016/j.brainresbull.2011.11.016 · DOI
  14. N Pankratz, 2012, Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2, Ann Neurol, 71, 370, 10.1002/ana.22687 · DOI · Paper page
  15. A Vellaichamy, 2010, “Topological significance” analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response, PLoS One, 5, e10936, 10.1371/journal.pone.0010936 · DOI
  16. S Jaeger, 2014, Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer, J Biomol Screen
  17. C Su, 2013, Using Bayesian networks to discover relations between genes, environment, and disease, BioData Min, 6, 6, 10.1186/1756-0381-6-6 · DOI
  18. C Taccioli, 2011, ParkDB: a Parkinson's disease gene expression database, Database (Oxford), 2011, bar007, 10.1093/database/bar007 · DOI
  19. D Bottomly, 2011, Evaluating gene expression in C57BL/6J and DBA/2J mouse striatum using RNA-Seq and microarrays, PLoS One, 6, e17820, 10.1371/journal.pone.0017820 · DOI · Paper page
  20. M Mooney, 2013, Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris, PLoS One, 8, e61088, 10.1371/journal.pone.0061088 · DOI
  21. JM Shoffner, 1991, Mitochondrial oxidative phosphorylation defects in Parkinson's disease, Ann Neurol, 30, 332, 10.1002/ana.410300304 · DOI · Paper page
  22. C Perier, 2012, Mitochondrial biology and Parkinson's disease, Cold Spring Harb Perspect Med, 2, a009332, 10.1101/cshperspect.a009332 · DOI · Paper page
  23. SJ Gardai, 2013, Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease, Plos One, e71634, 10.1371/journal.pone.0071634 · DOI · Paper page
  24. YJ Edwards, 2011, Identifying consensus disease pathways in Parkinson's disease using an integrative systems biology approach, PLoS One, 6, e16917, 10.1371/journal.pone.0016917 · DOI
  25. GT Sutherland, 2009, A cross-study transcriptional analysis of Parkinson's disease, PLoS One, 4, e4955, 10.1371/journal.pone.0004955 · DOI · Paper page
  26. A Dumitriu, 2012, Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation, PLoS Genet, 8, e1002794, 10.1371/journal.pgen.1002794 · DOI · Paper page
  27. P Carbonetto, 2013, Integrated enrichment analysis of variants and pathways in genome-wide association studies indicates central role for IL-2 signaling genes in type 1 diabetes, and cytokine signaling genes in Crohn's disease, PLoS Genet, 9, e1003770, 10.1371/journal.pgen.1003770 · DOI
  28. VK Mootha, 2003, PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes, Nat Genet, 34, 267, 10.1038/ng1180 · DOI · Paper page
  29. DJ Wong, 2005, Learning more from microarrays: insights from modules and networks, J Invest Dermatol, 125, 175, 10.1111/j.0022-202X.2005.23827.x · DOI
  30. YA Kim, 2011, Identifying causal genes and dysregulated pathways in complex diseases, PLoS Comput Biol, 7, e1001095, 10.1371/journal.pcbi.1001095 · DOI · Paper page
  31. LB Moran, 2006, Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease, Neurogenetics, 7, 1, 10.1007/s10048-005-0020-2 · DOI · Paper page
  32. O Myhre, 2013, Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures, Oxidative Medicine and Cellular Longevity, 2013, 10.1155/2013/726954 · DOI · Paper page
  33. M Cesani, 2014, Metallothioneins as dynamic markers for brain disease in lysosomal disorders, Ann Neurol, 75, 127, 10.1002/ana.24053 · DOI
  34. T Shachar, 2011, Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond, Mov Disord, 26, 1593, 10.1002/mds.23774 · DOI · Paper page
  35. T Hattori, 2012, Cognitive status correlates with white matter alteration in Parkinson's disease, Hum Brain Mapp, 33, 727, 10.1002/hbm.21245 · DOI · Paper page
  36. CL Rae, 2012, White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function, Neuroimage, 62, 1675, 10.1016/j.neuroimage.2012.06.012 · DOI · Paper page
  37. N Fabelo, 2011, Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease, Mol Med, 17, 1107, 10.2119/molmed.2011.00119 · DOI · Paper page
  38. A Koppelkamm, 2011, RNA integrity in post-mortem samples: influencing parameters and implications on RT-qPCR assays, Int J Legal Med, 125, 573, 10.1007/s00414-011-0578-1 · DOI
  39. JA Obeso, 2010, Missing pieces in the Parkinson's disease puzzle, Nat Med, 16, 653, 10.1038/nm.2165 · DOI · Paper page
  40. M Basso, 2004, Proteome analysis of human substantia nigra in Parkinson's disease, Proteomics, 4, 3943, 10.1002/pmic.200400848 · DOI · Paper page
  41. V Licker, 2012, Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease, J Proteomics, 75, 4656, 10.1016/j.jprot.2012.02.032 · DOI
  42. CJ Werner, 2008, Proteome analysis of human substantia nigra in Parkinson's disease, Proteome Sci, 6, 8, 10.1186/1477-5956-6-8 · DOI · Paper page
  43. B Schwanhausser, 2013, Corrigendum: Global quantification of mammalian gene expression control, Nature, 495, 126, 10.1038/nature11848 · DOI · Paper page
  44. MC Chartier-Harlin, 2011, Translation initiator EIF4G1 mutations in familial Parkinson disease, Am J Hum Genet, 89, 398, 10.1016/j.ajhg.2011.08.009 · DOI · Paper page
  45. J Jin, 2007, Identification of novel proteins associated with both alpha-synuclein and DJ-1, Mol Cell Proteomics, 6, 845, 10.1074/mcp.M600182-MCP200 · DOI · Paper page
  46. F Kthiri, 2010, Translational defects in a mutant deficient in YajL, the bacterial homolog of the parkinsonism-associated protein DJ-1, J Bacteriol, 192, 6302, 10.1128/JB.01077-10 · DOI
  47. J Trinh, 2013, Advances in the genetics of Parkinson disease, Nat Rev Neurol, 9, 445, 10.1038/nrneurol.2013.132 · DOI · Paper page
  48. Y Zhang, 2005, Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms, Am J Med Genet B Neuropsychiatr Genet, 137B, 5, 10.1002/ajmg.b.30195 · DOI · Paper page
  49. F Blandini, 2003, Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs, Ann N Y Acad Sci, 1010, 675, 10.1196/annals.1299.123 · DOI · Paper page
  50. PV Bondarenko, 2002, Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry, Anal Chem, 74, 4741, 10.1021/ac0256991 · DOI · Paper page
  51. AM Falick, 2011, ABRF-PRG07: advanced quantitative proteomics study, J Biomol Tech, 22, 21
  52. Z Khan, 2009, Protein quantification across hundreds of experimental conditions, Proc Natl Acad Sci U S A, 106, 15544, 10.1073/pnas.0904100106 · DOI · Paper page
  53. W Wang, 2003, Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards, Anal Chem, 75, 4818, 10.1021/ac026468x · DOI · Paper page
  54. R Edgar, 2002, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository, Nucleic Acids Res, 30, 207, 10.1093/nar/30.1.207 · DOI · Paper page
  55. RA Irizarry, 2003, Exploration, normalization, and summaries of high density oligonucleotide array probe level data, Biostatistics, 4, 249, 10.1093/biostatistics/4.2.249 · DOI · Paper page
  56. J Zhang, 2005, Detecting false expression signals in high-density oligonucleotide arrays by an in silico approach, Genomics, 85, 297, 10.1016/j.ygeno.2004.11.004 · DOI
  57. WE Johnson, 2007, Adjusting batch effects in microarray expression data using empirical Bayes methods, Biostatistics, 8, 118, 10.1093/biostatistics/kxj037 · DOI · Paper page
  58. GK Smyth, 2004, Linear models and empirical bayes methods for assessing differential expression in microarray experiments, Stat Appl Genet Mol Biol, 3, Article3, 10.2202/1544-6115.1027 · DOI · Paper page
  59. B Li, 2011, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome, BMC Bioinformatics, 12, 323, 10.1186/1471-2105-12-323 · DOI · Paper page
  60. W Huang da, 2007, DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists, Nucleic Acids Res, 35, W169, 10.1093/nar/gkm415 · DOI · Paper page
  61. S Bureeva, 2009, Manual annotation of protein interactions, Methods Mol Biol, 563, 75, 10.1007/978-1-60761-175-2_5 · doi:10.1007/978-1-60761-175-2_5
  62. M Ashburner, 2000, Gene ontology: tool for the unification of biology. The Gene Ontology Consortium, Nat Genet, 25, 25, 10.1038/75556 · DOI · Paper page
  63. M Bessarabova, 2012, Knowledge-based analysis of proteomics data, BMC Bioinformatics, 13 Suppl 16, S13, 10.1186/1471-2105-13-S16-S13 · DOI
  64. Z Dezso, 2009, Identifying disease-specific genes based on their topological significance in protein networks, BMC Syst Biol, 3, 36, 10.1186/1752-0509-3-36 · DOI
  65. C Gene Ontology, 2010, The Gene Ontology in 2010: extensions and refinements, Nucleic Acids Res, 38, D331, 10.1093/nar/gkp1018 · DOI · Paper page

Cited by

Metadata

Authors
Riley, B. E., Gardai, S. J., Emig-Agius, D., Bessarabova, M., Ivliev, A. E., Schüle, B., Alexander, J., Wallace, W., Halliday, G. M., Langston, J. W., Braxton, S., Yednock, T., Shaler, T., & Johnston, J. A.
Venue
PLoS ONE
Published
2014-08-29
Volume
9
Issue
8
Pages
e102909
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2067865628
Cited by
86
References
8
FWCI
3.10
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.